Skip to content

Effects of Topical Pirenoxine on Inflammation of Cornea After LASIK: A randomized controlled trial

Effects of Topical Pirenoxine on Inflammation of Cornea After LASIK: A randomized controlled trial

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
TCTR
Registry ID
TCTR20230320002
Enrollment
48
Registered
2023-03-20
Start date
2023-06-02
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Participants with refractive error who are LASIK candidates at Chiang Mai University LASIK center inflammation laser refractive surgery cornea

Interventions

Sponsors

Thailand Science Research and Innovation (TSRI)
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 40 Years

Inclusion criteria

Inclusion criteria: The difference of refractive error between eyes less than 1 diopter of spherical equivalence

Exclusion criteria

Exclusion criteria: 1) Any contraindications for laser refractive surgery including active ocular/ systemic diseases, corneal anatomy pathology, significant cataract, abnormal corneal topography/tomography, significant corneal thinning, unstable refractive error, having keloid or hypertrophic scar, and pregnant/ lactation 2) Presence of corneal scar or corneal opacity 3) Significant dry eye symptom in which ocular surface disease index (OSDI) > 18 4) Administration of oral antioxidant/vitamin supplements within 1 month 5) Using topical steroids/NSAIDs/pirenoxine within 1 month 6) Duration between screening visit and surgery less than 2 weeks 7) Using soft contact lens within 2 weeks 8) History of allergy to pirenoxine, artificial tears or their ingredients

Design outcomes

Primary

MeasureTime frame
Tear secretion At screening day, surgery day (before surgery) and after surgery (day 1, day 7, month 1, month 3 and month 6) Schirmer I test

Secondary

MeasureTime frame
Tear breakup time At screening day, surgery day (before surgery) and after surgery (day 1, day 7, month 1, month 3 and month 6) Clinical evaluation,Corneal staining At screening day, surgery day (before surgery) and after surgery (day 1, day 7, month 1, month 3 and month 6) Corneal staining grading score,Conjunctival hyperemia At screening day, surgery day (before surgery) and after surgery (day 1, day 7, month 1, month 3 and month 6) Conjunctival hyperemia grading score,Corneal opacity At screening day, surgery day (before surgery) and after surgery (month 1, month 3 and month 6) Corneal densitometry values, thickness of central white opacity from anterior segment ocular coherence tomography,Corneal nerve healing At screening day, surgery day (before surgery) and after surgery (day 1, day 7, month 1, month 3 and month 6) nerve growth factor (NGF) in tear fluid,Inflammation At screening day, surgery day (before and after surgery) and after surgery (day 1, day 7, month 1, month 3 and month 6) IL1, IL6, IL8, TNF, MCP-1

Countries

Thailand

Contacts

Public ContactPhit Upaphong

Faculty of Medicine, Chiang Mai University

phit.u@cmu.ac.th6653935512

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026